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Abstract 
 Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease 
characterized by extensive muscle weakness and eventual complete tetraplegia. The mdx mouse 
strain, which lacks a functional dystrophin protein, is the most frequently used small animal 
model in dystrophy research, but has limited pathological changes compared to patients with 
DMD. The mdx/mTR mouse strain, that lacks functional dystrophin and has depleted pools of 
muscle stem cells, is an emerging model of DMD. Previous reports have identified accelerated 
degeneration in mdx/mTR mice compared to mdx mice, but mdx/mTR mice have not been as 
extensively phenotyped. Therefore, to gain a greater understanding of the pathological changes 
present the mdx/mTR strain, we measured contractility of muscle fibers, and evaluated changes 
in the transcriptome with RNA sequencing, and in the proteome, metabolome, and lipidome 
using untargeted mass spectroscopy. The hindlimb muscles of four month old male wild type 
(WT) C57Bl/6 and mdx/mTR mice were used for analysis. We found no differences in the 
contractility of permeabilized muscle fibers between WT and mdx/mTR mice, but did observe 
divergent changes in the transcriptome and proteome, and changes in markers of skeletal muscle 
substrate metabolism that are informative about pathological changes in DMD.   
  
Introduction 
 Duchenne muscular dystrophy (DMD) is a rapidly progressing neuromuscular disease 
characterized by profound muscle weakness that leads to a near total loss of mobility, as well as 
other comorbidities that severely limit quality of life 1,2. The dystrophin gene, which is defective 
in patients with DMD, encodes a protein that plays a central role in transmitting forces generated 
by myofibrils within muscle fibers out to the extracellular matrix (ECM) which surrounds the 
muscle cell. The lack of dystrophin causes membrane shearing and other structural damage to 
muscle cells, which then leads to inflammation, scar tissue formation, and an eventual loss of 
muscle fibers 3-5. Although there have been numerous innovations in the treatment of patients 
with DMD that have provided some improvements in muscle function and extended lifespan, the 
additional years gained in lifespan are often spent in a tetraplegic state in which they are entirely 
dependent upon others for their care 1,2. Therefore, there is substantial room for improvement in 
our ability to treat the loss of strength in patients with DMD. 
 Mouse models of disease can serve an important role in providing additional information 
about the etiology of disease processes and can also be useful to screen potential therapies prior 
to conducting clinical trials. The mdx mouse contains a premature stop codon in exon 23 of the 
dystrophin gene resulting in a loss of a functional dystrophin protein, and this strain is the most 
commonly used preclinical model for the study of DMD 6. While mdx mice lack dystrophin, they 
have a generally mild limb muscle phenotype that does not mimic the pathological changes 
observed in patients with DMD 6. This deficiency has limited the utility of this model, and led to 
the development of additional mouse models with a phenotype that more closely parallels the 
human disease 6. One reason that mdx mice do not show the progressive loss in muscle quality 
that is observed in patients with DMD is due to species-specific differences in satellite cells, 
which are the myogenic stem cells responsible for regenerating injured fibers 7. Although 
dystrophin does play a role in self-renewal and proper asymmetric cell division 8, murine but not 
human satellite cells pools are thought to avoid depletion by inducing the expression of 
telomerase genes which restore telomere length that is severely shortened in response to 
proliferating throughout continued cycles of degeneration and regeneration 9. To address this and 
improve the mdx model, a new line of mice was generated in the mdx background in which the 
telomerase RNA component (Terc) gene was deleted 9. These genetically modified animals, 
referred to as mdx/mTR mice, display reduced satellite cell abundance and proliferative capacity, 
and a more pronounced muscle degenerative phenotype than mdx mice 9.  
 The mdx/mTR mouse model has been used in previous studies which have quantified 
whole muscle force production and other phenotypic changes 10, but the extent of our knowledge 
of pathological changes present in the mdx/mTR mouse model compared to other models of 
DMD are more limited. In particular, while mdx/mTR mice display reduced whole muscle force 
production 9, the mechanisms behind this loss in force production are not known. Additionally, 
changes to the metabolome or proteome of muscles from mdx/mTR mice have not been 
documented, as they have to some extent in other dystrophic models 11. To our knowledge, no 
previous report has comprehensively evaluated the pathological changes in an animal model of 
DMD which integrated untargeted transcriptomics, proteomics, metabolomics, and lipidomics. 
Therefore, to gain a greater understanding of the pathological changes present in mdx/mTR 
mice, we measured contractility of single, permeabilized muscle fibers, and evaluated changes in 
the transcriptome, proteome, metabolome, and lipidome in 4 month old male mdx/mTR mice, 
and compared these results directly to age-matched male wild type (WT) C57Bl/6 mice, and 
indirectly to other reported dystrophic models and studies of DMD patients in the literature.   
Results and Discussion 
Overview 
 We first sought to evaluate pathological changes in the hindlimb muscles of 4 month old 
WT and mdx/mTR mice, as the function of these muscles is important in maintaining 
ambulation. This age was selected to correspond to the approximate period of time when DMD 
patients begin to markedly lose mobility, as pathological changes are apparent in the muscles of 
mdx/mTR mice at 2 months of age 9. We also observed grossly reduced cage activity and lack of 
mobility beginning at 3 months of age in mdx/mTR mice. The muscles that were analyzed 
include the extensor digitorum longus (EDL), gastrocnemius (gastroc), plantaris, tibialis anterior 
(TA) and soleus. The EDL, gastroc, plantaris, and TA are composed of mostly fast (type II) 
muscle fibers, while the soleus has a mixed distribution of slow (type I) and fast fibers 12. 
Although we used different muscles to minimize the number of animals required to conduct this 
study, there is a substantial amount of similarity in the transcriptome of EDL, gastroc, plantaris, 
and TA muscles 13, and we think that conclusions from one of these fast fibered muscle groups 
can be extended to other muscles with similar fiber type distributions.  
 To gain a comprehensive view of changes in the transcriptome and proteome of skeletal 
muscles of mdx/mTR mice compared to WT mice, we performed mRNA sequencing (RNAseq) 
using TA muscles, and untargeted mass spectrometry-based proteomics of plantaris muscles. The 
principal component (PC) analysis of transcriptome data demonstrate divergence between WT 
and mdx/mTR mice (Figure 1A). A total of 14064 transcripts were detected and met appropriate 
expression cut-off thresholds, with 1791 transcripts demonstrating at least a 1.5-fold increase in 
expression and P<0.05, and 665 transcripts were at least 1.5-fold downregulated and 
significantly different (Figure 1B, Supplemental Table S1). To further increase the number of 
proteins that were analyzed, we analyzed the supernatant of homogenized plantaris muscles, as 
well as proteins extracted from the insoluble fraction. This resulted in the detection of 12 
additional proteins, in addition to 83 proteins that were already detected in the soluble fraction. 
Similar to the transcriptome, PC analysis of the proteome of WT and mdx/mTR groups also 
demonstrated divergence (Figure 2A). Of the 1237 proteins detected, 460 proteins had at least a 
1.5-fold increase in abundance and P<0.05, and 25 proteins were at least 1.5-fold downregulated 
and significantly different (Figure 2B, Supplemental Table S2). We then evaluated changes in 
the transcriptome compared with the proteome and identified 1119 proteins that also had 
transcripts that were detected in RNAseq (Figure 3A). Of these 1119 protein:transcript pairs, 
53.3% (95% confidence interval, 50.3-56.2%) had a fold change that was in the similar direction, 
while 46.7% (95% confidence interval, 43.8-49.7%) had a fold change of protein that did not 
match the direction of the transcript (Figure 3A). This distribution was significantly different 
than a random 50% distribution (Figure 3A). We then identified genes and proteins that have 
important roles in protein synthesis and degradation (Figure 3B), muscle fiber contractility and 
cytoskeletal architecture (Figure 3C), ECM (Figure 3D), and metabolism (Figure 3E), which will 
be discussed in subsequent sections. Additionally, qPCR analysis of a select set of genes was 
performed, and we generally observed similar directions in fold change directions between qPCR 
and RNAseq data (Table 1).  
 
Muscle Mass, Fiber Contractility, and the Extracellular Matrix 
 The mass of muscles was greater in mdx/mTR mice, demonstrating an increase from 23% 
in EDL muscles to 45% in TA muscles (Figure 4A), which is generally similar to previous 
reports of mdx mice 14. This elevated muscle mass was disproportionate to the 9% higher body 
mass of mdx/mTR mice (26.0±1.7g for WT, 28.3±0.9g for mdx/mTR, P=0.02). While we did not 
observe differences between wild type and mdx/mTR mice in terms of muscle fiber cross-
sectional area (CSA), the majority of muscle fibers of mdx/mTR mice contained centrally 
located nuclei, and fibrotic lesions were also noted (Figures 4B-D). This suggests that the 
increased mass of muscles of mdx/mTR mice is likely due to inflammation and an expansion of 
fibrotic ECM. This is supported by several findings from the RNAseq and proteomics data 
(Figure 3B). The major skeletal muscle calpains, µ-calpain (Capn1) and m-calpain (Capn2) were 
elevated in mdx/mTR muscles, along with cathepsin B (Ctsb) (Figure 3B). While the skeletal 
muscle specific E3 ubiquitin ligases MUSA1 (Fbxo30), atrogin-1 (Fbxo32), and MuRF-1 
(Trim63) were not upregulated, although the 20S proteasome subunit Psmb5 was upregulated, 
and signaling molecules that induce the activation of the ubiquitin ligase system, activin A 
(Inhba), activin B (Inhbb), and TGFβ (Tgfb1) were upregulated (Figure 3B). Several proteins or 
genes involved with translation were upregulated, including Eef1a1, Eif4a1, Rpl14, and Rps26 
(Figure 3A). These findings suggest that the muscles of mdx/mTR muscles are primed to 
synthesize new proteins to maintain muscle function, even though the cells continue to be 
damaged.  
 We next sought to evaluate muscle contractility. Previous studies in the EDL of 6-month 
old mdx mice demonstrated no difference in whole muscle maximum isometric force, but 
specific force, which is maximum isometric force normalized to muscle cross-sectional area 
(CSA), was reduced by 13% in mdx mice compared to WT controls 14. Further, when EDL 
muscles from mdx mice are subjected to a lengthening contraction-induced injury in which the 
muscle is suddenly lengthened while maximally activated, mdx mice experience a two-fold 
greater force deficit than WT mice, indicating greater damage to contractile elements of muscle 
fibers 15. However, at the single muscle fiber level, when comparing WT to mdx fibers there was 
no difference in maximum isometric force, specific force, or the force deficit in response to 
lengthening-contraction injury 16. The lack of any appreciable difference in the susceptibility of 
fibers from WT and mdx mice to injury was thought to occur as a result of the permeabilization 
disrupting the presence of dystrophin at the sarcolemma, although this was not directly addressed 
in the manuscript 16. We are unaware of any studies that have directly assessed the contractility 
of muscle fibers from DMD patients, but specific force values from a limited case series of 
patients with milder forms of muscular dystrophy appear generally to be lower than healthy 
controls 17-19. With this in mind, and because the specific force of intact lateral gastroc muscles 
from mdx/mTR mice was approximately 3.5-fold lower than WT mice 9 which is substantially 
greater than observations from mdx mice, we anticipated observing reductions in single fiber 
force production in mdx/mTR mice. However, there were no difference in the CSAs of 
permeabilized fibers, nor in maximum isometric force, specific force, or contraction-induced 
force deficits between wild type and mdx/mTR mice (Figure 5A-D). We then wanted to 
determine whether dystrophin was properly expressed at the sarcolemma, or if it was lost during 
the fiber permeabilization and isolation process. We performed a western blot for dystrophin in 
homogenates of approximately 30 permeabilized fibers pulled from bundles, and observed the 
presence of dystrophin in wild type muscles in western blots (Figure 5E). This was followed up 
by histology of permeabilized fibers demonstrating clear signal for dystrophin at the sarcolemma 
in wild type fibers, and as expected no signal was observed for fibers from mdx/mTR mice 
(Figure 5F). The typical myofibril striation pattern was maintained in mdx/mTR mice, 
supporting the contractile properties data, despite no pattern clearly demonstrating synthesis of 
sarcomere components such as α-actinin (Acta1), desmin (Des), moesin (Msn), myosin binding 
protein C (Mybpc2), myomesin (Myom1), myotilin (Myot), myozenin (Myoz1), myopalladin 
(Mypn), obscurin (Obscn), talin (Tln1), and the troponins (Tnn) (Figure 3C). For the myosin 
heavy chains, embryonic myosin heavy chain (Myh3) and perinatal myosin heavy chain (Myh8), 
which are expressed in regenerating fibers, were upregulated at the transcript level (Figure 3C). 
Additionally, while subsarcolemmal nuclei were present as expected in both WT and mdx/mTR 
mice, we also frequently observed collections of several nuclei immediately adjacent to each 
other and in a central location of the fiber (Figure 5F), consistent with a recent injury and 
myotube fusion event. This is supported by upregulation in the myoblast fusion protein 
myomaker (Tmem8c) and the membrane patching protein dysferlin (Dysf) (Figure 3C), which 
are also important in membrane repair in other models of DMD 20,21.  
 Overall, the lack of a difference between permeabilized fiber contractility of WT and 
mdx/mTR mice in the current study is consistent with previous findings in mdx mice 16. 
Although we expected to find altered force values at the single fiber level based on previously 
reported whole muscle data, whole muscle data was collected through direct nerve stimulation, 
and denervation and reduced EMG signal amplitude has been reported in mdx/mTR mice and in 
patients with DMD 22,23, which may result in reduced muscle activation and lower measured 
whole muscle forces. Additionally, by demonstrating that dystrophin remains at the sarcolemma 
in fibers of WT mice subjected to permeabilization, our findings support the notion that 
dystrophin plays little to no role in longitudinal force transmission within a muscle fiber. There is 
a clear role for dystrophin in the lateral transmission of force between fibers 24, and being able to 
transmit forces laterally between fibers also protects individual fibers from damage by 
distributing strain more evenly across fibers in a given muscle 25. In the absence of dystrophin, 
the ability to distribute strain across fibers in a muscle is lost, which likely explains why mdx 
mice display greater force deficits as a result of whole muscle lengthening contraction induced 
injuries 15, but there is no deficits at the single fiber level when force is nearly entirely 
transmitted longitudinally.  
 There were also pathological changes noted in the muscle ECM of mdx/mTR mice. In 
support of a fibrotic response, the muscle fibroblast markers PDGFRa and FSP1 (S100a4) were 
upregulated. There was an induction with nearly every gene that encodes an ECM-related 
protein, although there was some divergence between RNAseq and protein values (Figure 3D). 
Numerous proteoglycans such as biglycan (Bgn), decorin (Dcn), lumican (Lum), osteopontin 
(Spp1), tenascin C (Tnc), tenascin X (Tnxb), versican (Vcan), vinculin (Vcl), and vimentin 
(Vim) were upregulated at the transcript or protein level (Figure 3D), which is consistent with 
previous findings in 3 month old mdx and 6 month old mdx4cv animals 26,27. However, type Iα1 
and type Iα2 collagen had a lower abundance in mdx/mTR muscles, while type VIα1 collagen 
protein was not different despite having an elevation in transcript (Figure 3D). In 6 month old 
mdx4cv animals, which are thought to have a more severe muscle phenotype from the original 
strain of mdx mice, an elevation in type Iα1 and type VIα1 collagen protein was observed 27. It is 
possible that the differences between these results in collagen changes are due to an earlier 
degenerative stage of the mdx/mTR mice, prior to the onset of more severe fibrosis. Indeed, as 
fibrillar collagens play a role in longitudinal force transmission, and many proteoglycans assist in 
organizing the extracellular space that is linked with the dystrophin associated glycoprotein 
complexes 28, it is possible that the induction in proteoglycans occurs due to the repeated cycles 
of fiber damage and remodeling. Additionally, an elevation in the matrix metalloproteinases 
MMP-2, -3, and -14 was also observed, and these may be degrading fibrillar and basal lamina 
collagens (Figure 3D). 
 Overall, based on the observations in this study and previous reports, while there are 
pathological changes to muscle fibers and the ECM apparent in histology, these changes do not 
appear to disrupt the intrinsic force generating capacity of muscle fibers. However these changes 
likely disrupt lateral force transmission throughout the muscle ECM in mdx/mTR mice.  
 
Metabolomics and Lipidomics 
 Much of the previous work that has explored metabolic alterations that occur in DMD 
animal models has focused on cardiac muscle 11, but some studies have been performed in 
skeletal muscle tissue. Some limited studies in human subjects demonstrated reduced succinate 
and branched chain amino acids, increased glucose, triglycerides and cholesterol, and no 
difference in creatine/phosphocreatine or phospholipids in muscle biopsies in patients with DMD 
compared to controls 29,30. The muscles from golden retriever canines with a form of muscular 
dystrophy demonstrate reduced Krebs cycle intermediates compared to wild type animals 31 and 
similar reductions in oxidative capacity were also observed in the muscles of mdx mice 32. In the 
current study, we detected 62 metabolites in an untargeted mass spectroscopy platform. PC 
analysis demonstrated moderate overlap between the WT and mdx/mTR metabolome (Figure 
6A). We observed higher levels of metabolites involved with glycolysis in mdx/mTR mice, such 
as 6-phosphoglycerate (6PG), fructose-6-phosphate and glucose-6-phosphate (F6P+G6P), 
fructose bisphosphate (FBP), phosphorylated hexoses (hexose-P), and phosphoenolpyruvate 
(PEP), while the branched chain amino acid valine was not different (Figure 6A-B, Supplemental 
Table S3). Consistent with these changes in glycolytic metabolites, enzymes involved in 
glycolysis such as pyruvate kinase (Pkm) were upregulated, although no difference in aldolase A 
(Aldoa) was observed, and phosphoglycerate kinase 1 (Pgk1) and phosphorylase kinase (Phkb) 
were downregulated at the transcript level but protein abundance was not different (Figure 3E).  
 For Krebs cycle intermediates, no differences were observed between groups for acetyl-
phosphate (Acetyl-P), citrate and isocitrate (CIT+ICIT), or succinate, although malate was 
elevated (Figure 6B). Aconitase (Aco2) was not different at the transcript or protein level, while 
citrate synthase (Cs) and succinate dehydrogenase A (Sdha) transcripts were downregulated but 
had no differences in protein abundance, and myoglobin (Mb) RNA and protein were reduced in 
mdx/mTR muscles (Figure 3E). Additionally, neuronal nitric oxide synthase (nNOS or Nos1) is 
an enzyme located at the dystrophin glycoprotein complex that converts the amino acid L-
arginine to citrulline, and is known to be disrupted in patients with DMD 28. We observed a 
downregulation in nNOS gene expression (Figure 3E) along with an accumulation in L-arginine 
(Figure 6B), consistent with a functional deficit in nNOS activity in mdx/mTR mice. Overall, 
while glycolytic flux was reduced in mdx/mTR mice, differences in the Krebs cycle are less 
clear, and little changes in free amino acids were observed. 
 Finally, we analyzed the lipid content of muscles. PC analysis demonstrated a general 
dissimilarity between the lipidome of WT and mdx/mTR mice (Figure 7A). Of the 452 lipid 
species detected, there were 11 (2.4%) that were at least 1.5-fold elevated and significantly 
different in mdx/mTR muscles compared to WT, and 20 (4.4%) that were 1.5 fold lower and 
significantly different (Figure 7B, Supplemental Table S4). When analyzing lipid species by 
class instead of metabolite, ceramides (Cer), diglycerides (DG) and free fatty acids (FFA) were 
reduced in mdx/mTR muscles, with an elevation in phosphatidylglycerols (PG) and 
sphingomyelins (SM) (Figure 7C). These findings differ from a previous report of 3 month old 
mdx mice, which displayed an elevation of PC and PE, although both mdx and mdx/mTR mice 
did not have differences in PS abundance 33. Most of the enzymes involved in lipid uptake and 
storage were reduced at the RNA and protein level, such as fatty acid translocase (Cd36), acyl 
co-A synthetases (Acsl1 and Acss1), diacylglycerol o-acyltransferase 2 (Dgat2), fatty acid 
binding protein 3 (Fabp3), hormone sensitive lipase (Lipe), and perilipin 5 (Plin5). Additionally, 
enzymes involved in fatty acid uptake into mitochondria, such as carnitine acylcarnitine 
translocase (Slc25a20), and carnitine palmitoyltransferase (Cpt1b) were downregulated. For 
genes involved in β-oxidation of fatty acyl Co-As within the mitochondria, the medium and very 
long-chain acyl Co-A dehydrogenases (Acadm and Acadvl) were downregulated. Enzymes 
involved in the production of protaglandins and leukotrienes, such as leukotriene A4 hydrolase 
(Lta4h), and prostaglandin E synthase 2 and 3 (Ptges2 and Ptges3) were downregulated, although 
no difference in protein abundance was detected. Unlike glycolysis or Krebs cycle pathways, 
there is a clearer pattern present for lipid metabolism in mdx/mTR mice, with general signs that 
lipid oxidation capacity is likely reduced in this dystrophic mouse model.  
Limitations 
 There are several limitations to this work. We only evaluated mice at a single time point, 
chosen to be informative about the disease progression, but mdx/mTR mice are known to 
continue to develop pathological changes as they age. It is possible that extending the analysis to 
a later time point would demonstrate reductions in muscle fiber force production. Our analysis 
focused largely on fast fibered muscles, and other than histology and muscle mass, we did not 
evaluate changes in slow-fibered muscles like the soleus. We also did not evaluate the 
diaphragm, which is the most severely injured muscle in mouse models of DMD. Changes in the 
mRNA transcriptome were studied, and we did not evaluate other types of RNAs that play a role 
in muscle degeneration and regeneration. Mitochondrial respiration or the ability to metabolize 
glucose, fatty acids, and other substrates were not measured in real time, and conclusions about 
metabolic changes are based on static RNA, protein, and metabolite measures. We also only 
evaluated males in this study, as DMD is X-linked, however heterozygous females are known to 
have some muscle pathologies and reduced physical function. Despite these limitations, we feel 
that this work makes an important contribution to our understanding of pathological changes that 
occur in the muscles of mdx/mTR mice, and identifies several area for future exploration.  
 
Conclusions 
 In this study we performed a comprehensive evaluation of the muscle fiber contractile 
properties, and the transcriptome, proteome, metabolome, and lipidome in WT and mdx/mTR 
mice in an integrative manner. We provide additional support to the notion that dystrophin is not 
involved in the longitudinal transfer of force within muscle fibers, despite having a continued 
presence at the sarcolemma. Four months of age appears to be a time in the lifespan of mdx/mTR 
mice in which fibrotic changes to the ECM are limited, but important metabolic changes were 
noted. The findings of elevated glycolytic metabolism in mdx/mTR mice in this study may also 
be relevant to the emerging field of exercise prescription in patients with DMD. Since 
lengthening contractions are associated with muscle damage, rehabilitation programs are 
generally limited to isometric and shortening contractions 34. As low intensity, shortening 
contractions are associated with causing aerobic adaptations to muscles, and increased aerobic 
capacity is correlated with overall improved metabolic health and reductions in disease burden 35, 
low intensity exercise interventions may help patients with DMD to improve their quality of life. 
Additionally, although there are limitations in the translatability of findings from mdx/mTR mice 
to patients, this model is likely to be useful in preclinical evaluation of potential therapeutic 
interventions in patients with DMD.   
  
Methods 
 Animals. This study was approved by the University of Michigan IACUC (protocol 
PRO00006079). Mice were obtained from Jackson Labs (Bar Harbor, ME, USA) and housed 
under specific pathogen free conditions. Mice were allowed ad libidum access to food and water, 
but were fasted for four hours prior to harvest to minimize any impacts of acute food 
consumption on metabolomic measurements. We utilized male mdx/mTRG2 mice (referred to as 
mdx/mTR mice in this paper, Jackson Labs strain 023535) which are deficient for both the 
dystrophin and telomerase RNA component (Terc) genes 9. Wild type male C57BL/6J mice 
(referred to as WT mice in this paper, Jackson Labs strain 000664), which is the same 
background of the mdx/mTR mice, were used as controls. DNA obtained from tail biopsies, and 
genotype of animals was verified by PCR analysis of following guidelines of Jackson Labs. At 
four months of age, mice were injected with sodium pentobarbital via an intraperitoneal route to 
obtain deep anesthesia, tissues were harvested and weighed, and animals were humanely 
euthanized by anesthetic overdose followed by cervical dislocation. The tissues collected from 
both hindlimbs included the extensor digitorum longus (EDL), used for single fiber testing and 
histology; gastrocnemius (gastroc) muscles, used for histology; plantaris muscles, used for 
proteomics; soleus muscles, used for histology; and tibialis anterior (TA) muscles used for 
metabolomics/lipidomics and RNAseq/gene expression. A total of N=6 mice were used from 
each genotype, for a total of N=12 mice in the study.  
 RNA Sequencing (RNAseq) and Gene Expression. RNA was isolated from TA muscles 
using a miRNEasy kit (Qiagen, Valencia, CA, USA). RNA quality was assessed using a 
TapeStation (Agilent, Santa Clara, CA, USA) and all samples had a RNA integrity number 
greater than 9.0. For each sample, 250ng total RNA was delivered to the University of Michigan 
Sequencing Core for mRNA sequencing (RNAseq) analysis. Sample concentrations were 
normalized, cDNA pools were created for each sample and cDNAs were then subsequently 
tagged with a barcoded oligo adapter to allow for sample specific resolution. Sequencing was 
carried out using an Illumina HiSeq 4000 platform (Illumina, San Diego, CA, USA) with 50bp 
single end reads and an average of approximately 65 million reads per sample. Quality 
assessment and fold change calculations were performed in BaseSpace (Illumina). Sequencing 
data was quality checked using FastQC, aligned to the reference genome (mm10, UCSC, Santa 
Cruz, CA, USA) with the STAR software package, and differential expression based on 
fragments per kilobase of transcript per million mapped reads was performed using DESeq2. 
Genes with a base mean expression of at least 10 were used in analysis (a total of 14064 
transcripts met this threshold). 
 For gene expression analysis, RNA was reversed transcribed into cDNA using iScript 
Reverse Transcription Supermix (Bio-Rad). Quantitative PCR (qPCR) was performed with 
cDNA in a CFX96 real-time thermal cycler (Bio-Rad) using iTaq Universal SYBR Green 
Supermix (Bio-Rad). Target gene expression was normalized to the housekeeping gene β2-
microglobulin, and further normalized to WT samples using the 2-ΔΔCt method. Primer sequences 
are provided in Supplemental Table S5. 
 Proteomics. Proteomics was performed as reported in previous studies 36-38 at the 
University of Liverpool Centre of Proteome Research. Protein extraction of plantaris muscles 
was performed by first extracting soluble proteins from the homogenization supernatant, 
followed by second protein extraction of the remaining insoluble pellet of the muscle. Soluble 
proteins were extracted by homogenizing tissue in 25mM ammonium bicarbonate and 10mM 
iodoacetamide, followed by centrifugation and removal of the supernatant. Then 100µg of 
soluble protein was further reduced and alkylated, and in solution trypsin digestion was 
performed. The remaining pellet was resuspended in 500µl of 4M Guanidine-HCl extraction 
buffer (GnHCl), 65mM dithiothreitol, 50mM sodium acetate, pH 5.8 for 48 h at 4ºC with 
shaking. The samples were then centrifuged, the supernatant was removed, and 50µg of the 
soluble GnHCl fraction was subjected to in solution-trypsin digest on 10µl of resin (StrataClean, 
Agilent, Cheshire, UK) followed by reduction and alkylation. The digests from the isolated 
soluble proteins (5µL, corresponding to 2.5µg of peptides) and of those from GnHCl fraction 
(10µL, corresponding to 5 µg peptides) were loaded onto a spectrometer (Q-Exactive 
Quadrupole-Orbitrap, Thermo Scientific, Loughborough, UK) on a one hour gradient with an 
intersample 30 minute blank loaded.  
Raw spectra were converted to mgf files using Proteome Discovery (Thermo Scientific, 
Loughborough, UK) and resulting files were searched against the UniProt mouse sequence 
database using a Mascot server (Matrix Science, London, UK). Search parameters used were: 
peptide mass tolerance, 10ppm; fragment mass tolerance, 0.01Da;  +1,+2,+3 ions; missed 
cleavages 1; instrument type ESI-TRAP. Variable modifications included carbamidomethylation 
of cysteine residues and oxidation of methionine. Label free quantification was performed using 
PEAKS Studio software (BSI, Waterloo, ON, Canada). Proteins identified from the soluble and 
the insoluble fraction were combined for each group, and MetaboAnalyst 4.0 39 was used to 
quantify differences between groups.  
 Whole Muscle Histology. EDL, gastroc, and soleus muscles were snap frozen in 
tragacanth gum and stored at -80ºC until use. Muscles were sectioned at a thickness of 10µm, 
fixed with 4% paraformaldehyde, and then incubated in 0.2% Triton-X 100. Sections were then 
stained with wheat germ agglutinin (WGA) conjugated to AlexaFluor 555 (Thermo Fisher, 
Waltham, MA, USA) to label the extracellular matrix, and DAPI (Sigma, Saint Louis, MO, 
USA) to identify nuclei. Images of stained sections were taken on a microscope (BX51, 
Olympus, Waltham, MA, USA), and ImageJ (NIH, Bethesda, MD, USA) was used to quantify 
fiber CSAs and the percentage of muscle fibers with centrally located nuclei. 
 Muscle Fiber Contractility. The contractility of chemically permeabilized muscle fibers 
was performed as described 40,41. Briefly, fiber bundles were dissected from the EDL muscle, 
placed in skinning solution for 30 min and then in storage solution for 16 h at 4°C, followed by 
storage at -80°C. On the day of contractility assessment, samples were thawed slowly on ice, and 
individual fibres were pulled from bundles using fine mirror-finished forceps. Fibers were then 
placed in a chamber containing relaxing solution and secured at one end to a servomotor (Aurora 
Scientific, Aurora, ON, Canada) and the other end to a force transducer (Aurora Scientific) using 
two ties of 10-0 monofilament nylon suture (Ashaway Line & Twine, Ashaway, RI, USA). A 
laser diffraction measurement system was used to adjust fiber length to obtain a sarcomere length 
of 2.5µm. Mean fiber CSA was calculated assuming an elliptical cross-section, with diameters 
obtained at five positions along the fiber from high-magnification images taken from top and 
side views. Maximum isometric force (Fo) was elicited by immersing the fiber in a high calcium 
activation solution. Specific maximum isometric force (sFo) was calculated by dividing Fo by 
fiber CSA. The susceptibility of fibers to a lengthening contraction-induced injury was assessed 
by applying a single stretch to fully-activated fibers. The stretch was equivalent in amplitude to 
30% of fiber length, and was applied at a constant velocity of 0.5 fiber lengths per second. After 
the stretch, fibers were immediately returned to their original length and allowed to generate 
force until a new steady-state level was reached. The difference between the pre- and post-stretch 
forces was used to calculate force deficit, expressed as a percentage of pre-stretch Fo. Eight to ten 
fast fibers were tested from each EDL muscle. 
 Muscle Fiber Western Blot. Western blots of permeabilized muscle fibers was performed 
to evaluate the presence of dystrophin in fibers from samples that were pulled from bundles of 
WT and mdx/mTR muscles, as described above. Approximately 30 pulled fibers from each 
sample were homogenized in Laemmli’s sample buffer (Bio-Rad, Hercules, CA, USA), boiled 
for 2 minutes, and loaded into 7.5% polyacrylamide gels (Bio-Rad), and subjected to 
electrophoretic separation. Proteins were transferred to 0.2µm nitrocellulose membranes (Bio-
Rad) using a semi-dry transfer apparatus (Trans-Blot Turbo, Bio-Rad). Membranes were then 
blocked with 5% powdered milk, and incubated with polyclonal rabbit antibodies against 
dystrophin (ab15277, AbCam, Cambridge, MA, USA), and goat anti-rabbit antibodies 
conjugated to horse radish peroxidase (A16124, Thermo Fisher). Proteins were detected using 
enhanced chemiluminescence reagents (Clarity, Bio-Rad) and imaged in a chemiluminescent 
system (ChemiDoc MP, Bio-Rad). Following visualization of proteins, membranes were briefly 
stained with Coomassie (Bio-Rad) to verify similar protein loading between lanes.  
 Muscle Fiber Histology. To determine whether dystrophin persisted at the sarcolemma 
after permeabilization, fibers from WT and mdx/mTR samples were pulled from bundles that 
were prepared as described above, and subjected to histological processing using previously 
reported techniques 42. Fibers were fixed in 2% glutaraldehyde (Electron Microscopy Sciences, 
Hatfield, PA, USA), rinsed, and then incubated with phalloidin conjugated to AlexaFluor 555 
(Thermo Fisher) to identify actin, polyclonal rabbit antibodies against dystrophin (ab15277, 
AbCam), and DAPI (Sigma) to label nuclei. Goat anti-rabbit antibodies conjugated to 
AlexaFluor 647 (A21244, Thermo Fisher) were used to detect primary antibodies. Slides were 
imaged using a laser scanning confocal microscope (LSM 880, Zeiss, Thornwood, NY, USA).  
 Metabolomics and Lipidomics. The University of Michigan Metabolomics Core 
performed mass spectrometry-based shotgun lipidomics and metabolomics measurements from 
snap frozen, homogenized muscle samples as described 43,44. For lipidomics, lipids were 
extracted from samples with a solvent mixture consisting of 2:2:2 (v/v/v) 
methanol:dichloromethane:water mixture at room temperature after adding internal standard 
mixture. Once dried, the samples were resuspended in a solution containing 1:5:85 (v/v/v) 
acetonitrile:water:isopropanol and 10mM ammonium acetate. Samples were then subjected to 
liquid chromatrography-mass spectrometry (LC-MS), and MS peaks were matched in-silico with 
LipidBlast 45. Quantification was performed by Multiquant software (AB-SCIEX, Framingham, 
MA, USA). One WT sample failed quality control and was excluded from analysis. 
 For metabolomics, metabolites were extracted from frozen muscle in a solvent mixture 
containing 8:1:1 methanol:chloroform:water (v/v/v). Metabolites were derivatized and analyzed 
with gas chromatography-MS 46. Quantification of metabolites was performed using Masshunter 
Quantitative Analysis software (Agilent Technologies, Santa Clara, CA, USA).  
 MetaboAnalyst 4.0 39 was used to perform detailed statistical analyses for lipidomics and 
metabolomics assays.   
 Statistics. Values are presented as mean±SD. Differences between groups were assessed 
using t-tests (α=0.05). For RNAseq, proteomics, lipidomics, and metabolomics data, a FDR-
correction was applied to adjust for multiple observations. A binomial test (α=0.05) was used to 
compare the distribution of matched proteins and transcripts that have the same direction of fold 
change in mdx/mTR mice normalized to controls and in those which the direction of the fold 
change of the protein is different from the transcript. A Wilson/Brown approach was used to 
generate 95% confidence intervals for the percent distribution. With the exception of analyses 
performed in DESeq2 or MetaboAnalyst, statistical calculations were performed using Prism 
software (version 8.0, GraphPad, San Diego, CA, USA).  
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Figure Legends 
 Figure 1. RNA sequencing. (A) Principal component (PC) analysis of RNA sequencing 
data. (B) Volcano plot demonstrating log2 fold-change and FDR-corrected P-values of all 
measured transcripts. Genes with -log10P values greater than 10 are shown directly on the top 
border of the graph. Genes with a > 1.5-fold upregulation in mdx/mTR mice (log2 fold change > 
0.585) and P value < 0.05 (-log10P > 1.301) are shown in red. Genes with a > 1.5-fold 
downregulation in mdx/mTR mice (log2 fold change < -0.585) and P value < 0.05 (-log10P > 
1.301) are shown in blue. N=6 WT and N=6 mdx/mTR mice per group.  
 Figure 2. Proteomics. (A) Principal component (PC) analysis of proteomics data. (B) 
Volcano plot demonstrating log2 fold-change and FDR-corrected P-values of all measured 
proteins. Proteins with a > 1.5-fold increase in mdx/mTR mice (log2 fold change > 0.585) and P 
value < 0.05 (-log10P > 1.301) are shown in red. Genes with a > 1.5-fold decrease in mdx/mTR 
mice (log2 fold change < -0.585) and P value < 0.05 (-log10P > 1.301) are shown in blue. N=6 
WT and N=6 mdx/mTR mice per group. 
 Figure 3. Integrated RNA sequencing and Proteomics. (A) Overview of the total 
number of transcripts and proteins detected, the number of proteins that matched to transcripts, 
and the percentage (with 95% confidence interval) of matched proteins and transcripts that have 
the same direction of fold change in mdx/mTR mice normalized to controls (gray), and those in 
which the direction of the fold change of the protein is different from the transcript (black). A 
binomial test was performed to compare the observed distribution to the expected distribution. 
Heatmap demonstrating the log2 fold change in selected genes and proteins related to (B) protein 
synthesis and degradation, (C) contractility and the cytoskeleton, (D) the extracellular matrix, 
and (E) metabolism. Black box indicates that the protein was not present in the proteomics data 
set. Differences between groups (B-E) assessed using t-tests; *, significantly different (P<0.05) 
from WT. N=6 WT and N=6 mdx/mTR mice. 
 Figure 4. Muscle Mass and Histology. (A) Muscle mass data from extensor digitorum 
longus (EDL), gastrocnemius (gastroc), plantaris, tibialis anterior (TA) and soleus muscles. (B) 
Histological cross-sectional area (CSA) and (C) fibers that contain centrally located nuclei, 
expressed as a percentage of total fibers. (D) Representative histology from WT and mdx/mTR 
gastroc muscles; red, WGA-AF555/extracellular matrix; blue, DAPI/nuclei. Scale bar for both 
images is 50µm. Values are mean+SD, differences between groups assessed using t-tests; *, 
significantly different (P<0.05) from WT. N=6 WT and N=6 mdx/mTR mice. 
 Figure 5. Permeabilized Extensor Digitorum Longus Muscle Fiber Force and Fiber 
Morphology. (A) Permeabilized fiber cross-sectional area (CSA), (B) maximum isometric force, 
(C) specific force, and (D) force deficit after active stretch induced injury. Values are mean+SD, 
differences between groups assessed using t-tests; no differences detected between WT and 
mdx/mTR groups. N=6 WT and N=6 mdx/mTR mice. (E) Western blot and (F) histology of 
permeabilized fibers demonstrating the presence of dystrophin at the sarcolemma of fibers after 
the permeabilization process; red, actin; blue, DAPI/nuclei; white, dystrophin. Scale bar in both 
images is 20µm.  
 Figure 6. Metabolomics. (A) Principal component (PC) analysis of metabolomics data. 
(B) Heatmap demonstrating the log2 fold change in selected metabolites involved in the creatine 
phosphate shuttle, glycolysis, Krebs cycle, glutathione metabolism, nucleotide and nucleoside 
metabolism, as well as free amino acids: creatine (Cr), phospho-creatine (P-Cr), 2-
phosphoglycerate and 3-phosphoglycerate (2PG+3PG), 6-phosphoglycerate (6PG), fructose-6-
phosphate and glucose-6-phosphate (F6P+G6P), fructose bisphosphate (FBP), glyceraldehyde 3-
phosphate (G3P), hexose-phosphates (Hexose-P), phosphoenolpyruvate (PEP), ribulose 5-
phosphate and xylulose 5-phosphate (R5P+X5P), sedoheptulose 7-phosphate (S7P), acetyl-
phosphate (Acetyl-P), citrate and isocitrate (CIT+ICIT), reduced glutathione (GSH), oxidized 
glutathione (GSSG), adenosine diphosphate (ADP), adenosine monophosphate (AMP), 
adenosine triphosphate (ATP), flavin adenine dinucleotide (FAD), guanosine diphosphate 
(GDP), guanosine monophosphate (GMP), inosine monophosphate (IMP), N-Acetyl-
glucosamine-1-phosphate (N-A-G1P), nicotinamide adenine dinucleotide (NAD), nicotinamide 
adenine dinucleotide phosphate (NADP), uridine diphosphate (UDP), uridine diphosphate-D-
glucose (UDP-D-G), uridine diphosphate-N-acetyl-D-glucosamine (UDP-N-D-G), uridine 
monophosphate (UMP), uridine triphosphate (UTP). Differences between groups assessed using 
t-tests; *, significantly different (P<0.05) from WT. N=6 WT and N=6 mdx/mTR mice. 
 Figure 7. Lipidomics. (A) Principal component (PC) analysis of lipidomics data. (B) 
Volcano plot demonstrating fold-change and FDR-corrected P-values of all measured lipid 
species. Lipid species with a > 1.5-fold increase in mdx/mTR mice (log2 fold change > 0.585) 
and P value < 0.05 (-log10P > 1.301) are shown in red. Lipid species with a > 1.5-fold decrease in 
mdx/mTR mice (log2 fold change < -0.585) and P value < 0.05 (-log10P > 1.301) are shown in 
blue. (C) Heatmap demonstrating the log2 fold change in classes of lipids: Cholesterol ester (CE), 
ceramides (Cer), cardiolipins (CL), diglycerides (DG), free fatty acids (FFA), 
lysophosphatidylcholines (LysoPC), lysophosphatidylethanolamines (LysoPE), monoglycerides 
(MG), phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylglycerols (PG), 
phosphatidylinositols (PI), plasmenyl phosphatidylcholines (Plasmenyl-PC), plasmenyl 
phosphatidylethanolamines (Plasmenyl PE), phosphatidylserines (PS), sphingomyelins (SM), 
and triglycerides (TG). Differences between groups assessed using t-tests; *, significantly 
different (P<0.05) from WT. N=5 WT and N=6 mdx/mTR mice. 
  
 Table 1. Changes in gene expression as measured by qPCR. Gene expression values 
from tibialis anterior muscles. Values are mean±CV, differences tested between groups using t-
tests; *, significantly different (P<0.05) from WT. N=6 WT and 6 mdx/mTR mice. 
 
Gene WT mdx/mTR 
Col1a1 1.00±0.47 2.19±1.09* 
Col5a1 1.00±0.29 1.50±0.63 
Dgat2 1.00±0.76 0.42±0.41 
Fbxo32 1.00±0.88 0.72±0.57 
Mmp14 1.00±0.35 2.00±0.95* 
Mstn 1.00±0.52 0.38±0.23* 
Myh8 1.00±0.50 35.9±25.0* 
Tmem8c 1.00±0.44 16.7±8.30* 
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